Top

Published in:

01-10-2010 | Topic Review

Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging

Authors: Rajan Jain, Jayant Narang, Pia M. Sundgren, David Hearshen, Sona Saksena, Jack P. Rock, Jorge Gutierrez, Tom Mikkelsen

Published in: Journal of Neuro-Oncology | Issue 1/2010

Abstract

Brain tumor patients undergo various combinations therapies, leading to very complex and confusing imaging appearances on follow up MR imaging and hence, differentiating recurrent or progressing tumors from treatment induced necrosis or effects has always been a challenge in neuro-oncologic imaging. This particular topic has become more relevant these days because of the advent of newer anti-angiogenic and anti-neoplastic chemotherapeutic agents as well as use of salvage radiation therapy. Various clinically available functional imaging modalities can provide additional physiologic and metabolic information about the tumors which could be useful in identifying viable tumor from treatment induced necrosis and hence, can guide treatment planning. In this review we will discuss various functional neuro-imaging modalities, their advantages and limitations and also their utility in treatment planning.

Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81–83CrossRefPubMed

Clarke JL, Chang S (2009) Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep 9:241–246CrossRefPubMed

Lyubimova N, Hopewell JW (2004) Experimental evidence to support the hypothesis that damage to vascular endothelium plays the primary role in the development of late radiation-induced CNS injury. Br J Radiol 77:488–492CrossRefPubMed

Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998CrossRefPubMed

Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624–6628PubMed

Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK (2008) Response criteria for glioma. Nat Clin Pract Oncol 5:634–644CrossRefPubMed

Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845CrossRefPubMed

Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314CrossRefPubMed

Jain R, Scarpace L, Ellika S, Schultz L, Torcuator R, Hearshen D, Mikkelsen T Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker. J Neurooncol (in press)

10.

Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A (2008) High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol 10:700–708CrossRefPubMed

11.

Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377–384PubMed

12.

Mullins ME, Barest GD, Schaefer PW, Hochberg FH, Gonzalez RG, Lev MH (2005) Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol 26:1967–1972PubMed

13.

Rogers LR, Scarpace L, Guitterez J, Lord B, Ryu S, Movsas B, Honsowetz J, Rosenblum M, Jain R (2006) Magnetic resonance imaging characteristics and histological correlates of cerebral radiation necrosis. Neurology 66(Suppl 2):335

14.

Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329–336CrossRefPubMed

15.

Henson JW, Ulmer S, Harris GJ (2008) Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 29:419–424CrossRefPubMed

16.

Jain RK, Tong RT, Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67:2729–2735CrossRefPubMed

17.

Chong VF, Rumpel H, Fan YF, Mukherji SK (2001) Temporal lobe changes following radiation therapy: imaging and proton MR spectroscopic findings. Eur Radiol 11:317–324CrossRefPubMed

18.

Hein PA, Eskey CJ, Dunn JF, Hug EB (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25:201–209PubMed

19.

Inoue T, Ogasawara K, Beppu T, Ogawa A, Kabasawa H (2005) Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas. Clin Neurol Neurosurg 107:174–180CrossRefPubMed

20.

Meyer MA, Frey KA, Schwaiger M (1993) Discordance between F-18 fluorodeoxyglucose uptake and contrast enhancement in a brain abscess. Clin Nucl Med 18:682–684CrossRefPubMed

21.

Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D, Johnson G (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490–498CrossRefPubMed

22.

Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G (2004) Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 25:746–755PubMed

23.

Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 238:658–667CrossRefPubMed

24.

Jain R, Ellika SK, Scarpace L, Schultz LR, Rock JP, Gutierrez J, Patel SC, Ewing J, Mikkelsen T (2008) Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. AJNR Am J Neuroradiol 29:694–700CrossRefPubMed

25.

Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848CrossRefPubMed

26.

Jain RK (2002) Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29:3–9PubMed

27.

Ellika SK, Jain R, Patel SC, Scarpace L, Schultz LR, Rock JP, Mikkelsen T (2007) Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. AJNR Am J Neuroradiol 28:1981–1987CrossRefPubMed

28.

Covarrubias DJ, Rosen BR, Lev MH (2004) Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 9:528–537CrossRefPubMed

29.

Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S (2009) Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 30:367–372CrossRefPubMed

30.

Sugahara T, Korogi Y, Tomiguchi S, Shigematsu Y, Ikushima I, Kira T, Liang L, Ushio Y, Takahashi M (2000) Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 21:901–909PubMed

31.

Jain R, Scarpace L, Ellika S, Schultz LR, Rock JP, Rosenblum ML, Patel SC, Lee TY, Mikkelsen T (2007) First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 61:778–786 Discussion 786–777CrossRefPubMed

32.

Gaensler EH, Dillon WP, Edwards MS, Larson DA, Rosenau W, Wilson CB (1994) Radiation-induced telangiectasia in the brain simulates cryptic vascular malformations at MR imaging. Radiology 193:629–636PubMed

33.

Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989CrossRefPubMed

34.

Kamiryo T, Lopes MB, Kassell NF, Steiner L, Lee KS (2001) Radiosurgery-induced microvascular alterations precede necrosis of the brain neuropil. Neurosurgery 49:409–414 Discussion 414–405CrossRefPubMed

35.

Chong VF, Rumpel H, Aw YS, Ho GL, Fan YF, Chua EJ (1999) Temporal lobe necrosis following radiation therapy for nasopharyngeal carcinoma: 1H MR spectroscopic findings. Int J Radiat Oncol Biol Phys 45:699–705PubMed

36.

Weybright P, Sundgren PC, Maly P, Hassan DG, Nan B, Rohrer S, Junck L (2005) Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 185:1471–1476CrossRefPubMed

37.

Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC (2009) Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. Am J Roentgenol 192:W45–W52CrossRef

38.

Rock JP, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, Rosenblum M, Mikkelsen T (2004) Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54:1111–1117 Discussion 1117–1119CrossRefPubMed

39.

Sundgren PC (2009) MR spectroscopy in radiation injury. AJNR Am J Neuroradiol 30:1469–1476CrossRefPubMed

40.

Rabinov JD, Lee PL, Barker FG, Louis DN, Harsh GR, Cosgrove GR, Chiocca EA, Thornton AF, Loeffler JS, Henson JW, Gonzalez RG (2002) In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 225:871–879CrossRefPubMed

41.

Schlemmer HP, Bachert P, Henze M, Buslei R, Herfarth KK, Debus J, van Kaick G (2002) Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 44:216–222CrossRefPubMed

42.

Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, van Kaick G (2001) Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol 22:1316–1324PubMed

43.

Esteve F, Rubin C, Grand S, Kolodie H, Le Bas JF (1998) Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys 40:279–286PubMed

44.

Kaminaga T, Shirai K (2005) Radiation-induced brain metabolic changes in the acute and early delayed phase detected with quantitative proton magnetic resonance spectroscopy. J Comput Assist Tomogr 29:293–297CrossRefPubMed

45.

Castillo M, Kwock L, Mukherji SK (1996) Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol 17:1–15PubMed

46.

Tien RD, Felsberg GJ, Friedman H, Brown M, MacFall J (1994) MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. AJR Am J Roentgenol 162:671–677PubMed

47.

Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60CrossRefPubMed

48.

Gupta RK, Sinha U, Cloughesy TF, Alger JR (1999) Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 41:2–7CrossRefPubMed

49.

Castillo M, Smith JK, Kwock L, Wilber K (2001) Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 22:60–64PubMed

50.

Guo AC, Cummings TJ, Dash RC, Provenzale JM (2002) Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 224:177–183CrossRefPubMed

51.

Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92:2029–2036CrossRefPubMed

52.

Hamstra DA, Galban CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien C, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, Ross BD, Chenevert TL (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387–3394CrossRefPubMed

53.

Field AS, Alexander AL, Wu YC, Hasan KM, Witwer B, Badie B (2004) Diffusion tensor eigenvector directional color imaging patterns in the evaluation of cerebral white matter tracts altered by tumor. J Magn Reson Imaging 20:555–562CrossRefPubMed

54.

Morita K, Matsuzawa H, Fujii Y, Tanaka R, Kwee IL, Nakada T (2005) Diffusion tensor analysis of peritumoral edema using lambda chart analysis indicative of the heterogeneity of the microstructure within edema. J Neurosurg 102:336–341CrossRefPubMed

55.

Basser PJ, Pierpaoli C (1996) Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 111:209–219CrossRefPubMed

56.

Wiegell MR, Henson JW, Tuch DS, Sorensen AG: Diffusion tensor imaging shows potential to differentiate infiltrating from non-infiltrating tumors. In: Proceedings of the international society for magnetic resonance in medicine (ISMRM) eleventh scientific meeting, Toronto, Ontario, Canada, p 2075

57.

Sundgren PC, Fan X, Weybright P, Welsh RC, Carlos RC, Petrou M, McKeever PE, Chenevert TL (2006) Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 24:1131–1142CrossRefPubMed

58.

Le Bihan D, Douek P, Argyropoulou M, Turner R, Patronas N, Fulham M (1993) Diffusion and perfusion magnetic resonance imaging in brain tumors. Top Magn Reson Imaging 5:25–31CrossRefPubMed

59.

Tung GA, Evangelista P, Rogg JM, Duncan JA 3rd (2001) Diffusion-weighted MR imaging of rim-enhancing brain masses: is markedly decreased water diffusion specific for brain abscess? AJR Am J Roentgenol 177:709–712PubMed

60.

Biousse V, Newman NJ, Hunter SB, Hudgins PA (2003) Diffusion weighted imaging in radiation necrosis. J Neurol Neurosurg Psychiatry 74:382–384CrossRefPubMed

61.

Zhou XJ, Leeds NE, Kumar AJ, Chong J, Levin VA: Differentiation of tumor recurrence from treatment-induced necrosis using quantitative diffusion MRI. In: Proceedings, ninth scientific meeting, international society of magnetic resonance in medicine, Glasgow, Scotland, UK, p 726

62.

Asao C, Korogi Y, Kitajima M, Hirai T, Baba Y, Makino K, Kochi M, Morishita S, Yamashita Y (2005) Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 26:1455–1460PubMed

63.

Sinha S, Bastin ME, Whittle IR, Wardlaw JM (2002) Diffusion tensor MR imaging of high-grade cerebral gliomas. AJNR Am J Neuroradiol 23:520–527PubMed

64.

Nagesh V, Tsien CI, Chenevert TL, Ross BD, Lawrence TS, Junick L, Cao Y (2008) Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys 70:1002–1010PubMed

65.

Kashimura H, Inoue T, Beppu T, Ogasawara K, Ogawa A (2007) Diffusion tensor imaging for differentiation of recurrent brain tumor and radiation necrosis after radiotherapy—three case reports. Clin Neurol Neurosurg 109:106–110CrossRefPubMed

66.

Chao ST, Suh JH, Raja S, Lee SY, Barnett G (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96:191–197CrossRefPubMed

67.

Stokkel M, Stevens H, Taphoorn M, Van Rijk P (1999) Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera—a pilot study. Nucl Med Commun 20:411–417CrossRefPubMed

68.

Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, Otsuka Y, Sakamoto S, Ohata K, Goto T, Hara M (2003) Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 98:1056–1064CrossRefPubMed

69.

Patronas NJ, Di Chiro G, Brooks RA, DeLaPaz RL, Kornblith PL, Smith BH, Rizzoli HV, Kessler RM, Manning RG, Channing M, Wolf AP, O’Connor CM (1982) Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 144:885–889PubMed

70.

Kim CK, Alavi JB, Alavi A, Reivich M (1991) New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 10:85–91CrossRefPubMed

71.

De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746–750CrossRefPubMed

72.

Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, Ra YS, Yeo JS, Ryu JS, Moon DH (2005) [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 32:653–659CrossRefPubMed

73.

Spence AM, Muzi M, Link JM, O’Sullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA (2009) NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3′-deoxy-3′-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol 11:343–355CrossRefPubMed

74.

Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911PubMed

75.

Huisman TA, Loenneker T, Barta G, Bellemann ME, Hennig J, Fischer JE, Il’yasov KA (2006) Quantitative diffusion tensor MR imaging of the brain: field strength related variance of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) scalars. Eur Radiol 16:1651–1658CrossRefPubMed

76.

Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK (2009) A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296–5300CrossRefPubMed

77.

Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, Rehemtulla A, Ross BD (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15:572–576CrossRefPubMed

78.

Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182–189CrossRefPubMed

79.

Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, Ross BD (2006) The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8:259–267CrossRefPubMed

Title: Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging
Authors: Rajan Jain
Jayant Narang
Pia M. Sundgren
David Hearshen
Sona Saksena
Jack P. Rock
Jorge Gutierrez
Tom Mikkelsen
Publication date: 01-10-2010
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0139-3

At a glance: The STEP trials

Springer Medicine

Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients

Decreased pygopus 2 expression suppresses glioblastoma U251 cell growth

Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA–substance P—results from a phase I study

Protection of normal brain cells from γ-irradiation-induced apoptosis by a mitochondria-targeted triphenyl-phosphonium-nitroxide: a possible utility in glioblastoma therapy

Descriptive epidemiology of selected olfactory tumors

Huge cranio-cerebral rhabdomyosarcoma in HIV-positive patient